Evidence map›Paper›PMID 29728694›Full record

ArticleLeukemia2018

Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.

Weili Sun, Jemily Malvar, Richard Sposto, Anupam Verma, Jennifer J Wilkes, Robyn Dennis, Kenneth Heym, Theodore W Laetsch, Melissa Widener, Susan R Rheingold and 20 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07502118 (An Open-Label, Multicenter Phase 2-3 Clinical Study of Anti-CD19 Chimeric Antigen Receptor T Cells), which is not on this map. Cited by 77 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07502118 phase2 / phase3recruitingnot on this mapstarted 2025, after this paper: background citation

An Open-Label, Multicenter Phase 2-3 Clinical Study of Anti-CD19 Chimeric Antigen Receptor T Cells (Talikabtagene Autoleucel) in Patients With Relapsed/Refractory B-Cell Malignancies (NexCAR19)

TypeinterventionalSponsorHealth Institutes of TurkeyRan2025 to 2030Enrolled40ConditionsRelapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBCL)ArmsTalikabtagene Autoleucel
3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Weili SunCity of Hope National Medical Center, Duarte, CA, USA. weilisun@coh.org.
Jemily MalvarChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Richard SpostoChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Anupam VermaPrimary Children's Hospital, Pediatric Hematology/Oncology, University of Utah, Salt Lake City, UT, USA.
Jennifer J WilkesSeattle Children's Hospital, University of Washington, Seattle, WA, USA.
Robyn DennisNationwide Children's Hospital, the Ohio State University, Columbus, OH, USA.
Kenneth HeymCook Children's Medical Center, Fort Worth, TX, USA.
Theodore W LaetschUT Southwestern Medical Center/ Children's Health, Dallas, TX, USA.
Melissa WidenerCenter for Cancer & Blood Disorders, Children's Hospital Colorado, Aurora, CO, USA.
Susan R RheingoldChildren's Hospital of Philadelphia, Philadelphia, PA, USA.
Javier OesterheldLevine Children's Hospital at Carolinas Medical Center, Charlotte, NC, USA.
Nobuko HijiyaAnn & Robert H Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Maria Luisa SulisNew York Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA.
Van HuynhChildren's Hospital Orange County, Hyundai Cancer Institute, Orange, CA, USA.
Andrew E PlaceDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.
Henrique BittencourtCHU Sainte-Justine, Universite de Montreal, Montreal, QC, Canada.
Raymond HutchinsonC.S Mott Children's Hospital, University of Michigan, Ann Arbor, MI, USA.
Yoav MessingerChildren's Hospital of Minnesota, Minneapolis, MN, USA.
Bill ChangDoernbecher Children's Hospital, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Yousif MatloubRainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
David S ZieglerKids Cancer Center, Sydney Children's Hospital, School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-7451-7916
Rebecca GardnerSeattle Children's Hospital, University of Washington, Seattle, WA, USA.
Todd CooperSeattle Children's Hospital, University of Washington, Seattle, WA, USA.
Francesco CeppiDepartment of Pediatrics, University of Lausanne, Lausanne, Switzerland.
Michelle HermistonBenioff Children's Hospital, University of California, San Francisco, CA, USA.
Luciano Dalla-PozzaCancer Center for Children, The Children's Hospital at Westmead, Westmead, NSW, Australia.
Kirk R SchultzBC Children's Hospital and Research Institute, University of British Columbia, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0002-0001-6438
Paul GaynonChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Alan S WayneChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
James A WhitlockThe Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The survival of pediatric patients with multiply relapsed and/or refractory (R/R) B-cell acute lymphoblastic leukemia has historically been very poor; however, data are limited in the current era. We conducted a retrospective study to determine the outcome of multiply R/R childhood B-ALL treated at 24 TACL institutions between 2005 and 2013. Patient information, treatment, and response were collected. Prognostic factors influencing the complete remission (CR) rate and event-free survival (EFS) were analyzed. The analytic set included 578 salvage treatment attempts among 325 patients. CR rates (mean ± SE) were 51 ± 4% for patients with bone marrow R/R B-ALL who underwent a second salvage attempt, 37 ± 6% for a third attempt, and 31 ± 6% for the fourth through eighth attempts combined. For patients achieving a CR after their second, third, and fourth through eighth attempts, the 2 year EFS was 41 ± 6%, 13 ± 7%, and 27 ± 13% respectively. Our results showed slight improvement when compared to previous studies. This is the largest and most recent study to date that evaluates the outcome of this patient population. Our data will provide detailed reference for the evaluation of new agents being developed for childhood B-ALL.

Indexed as

Antineoplastic AgentsB-LymphocytesBone MarrowChildChild, PreschoolDisease-Free SurvivalFemaleHumansInfantMaleNeoplasm Recurrence, LocalPrecursor B-Cell Lymphoblastic Leukemia-LymphomaRemission InductionRetrospective StudiesSalvage TherapyAntineoplastic Agents

Identifiers

PMID29728694
PMCPMC6224404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.